UBS upgraded Genmab to Buy from Neutral with a price target of DKK 2,800, down from DKK 3,000. The company’s oncology pipeline has been “largely ignored” despite a “highly differentiated” and advanced’ portfolio in the novel immuno-oncology space, the analyst tells investors in a research note. The firm says Genmab’s oncology assets are an alternative potential solution to the Darzalex patent cliff.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on GMAB:
- Capital Increase in Genmab as a Result of Employee Warrant Exercise
- AbbVie (NYSE:ABBV) Slips despite New Drug Win
- Genmab announces regulatory update for epcoritamab
- Genmab Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®/TEPKINLY®) for the Treatment of Relapsed/Refractory Follicular Lymphoma
- Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons